Pharmaceutical Manufacturing Handbook: Production and

REFERENCES 721
170. Ward , G. H. , and Schultz , R. K. ( 1995 ), Process - induced crystallinity changes in albuterol
sulfate and its effect on powder physical stability , Pharm. Res. , 12 , 773 – 779 .
171. Giry , K. , Pean , J. M. , Giraud , L. , Marsas , S. , Rolland , H. , and Wuthrich , P. ( 2006 ), Drug/
lactose co - micronization by jet milling to improve aerosolization properties of a powder
for inhalation , Int. J. Pharm , 321 , 162 – 166 .
172. Rasenack , N. , and Muller , B. W. ( 2004 ), Micron - size drug particles: Common and novel
micronization techniques , Pharm. Dev. Technol. , 9 , 1 – 13 .
173. Steckel , H. , Rasenack , N. , Villax , P. , and Muller , B. W. ( 2003 ), In vitro characterization
of jet - milled and in - situ - micronized fl uticasone - 17 - propionate , Int. J. Pharm. , 258 , 65 –
75 .
174. Edwards , D. A. , Ben - Jebria , A. , and Langer , R. ( 1998 ), Recent advances in pulmonary
drug delivery using large, porous inhaled particles , J. Appl. Physiol. , 85 , 379 – 385 .
175. White , S. , Bennett , D. B. , and Cheu , S. , et al. ( 2005 ), EXUBERA: Pharmaceutical development
of a novel product for pulmonary delivery of insulin , Diabetes Technol. Ther. , 7 ,
896 – 906 .
176. Vanbever , R. , Mintzes , J. D. , Wang , J. , et al. ( 1999 ), Formulation and physical characterization
of large porous particles for inhalation , Pharm. Res. , 16 , 1735 – 1742 .
177. Dunbar , C. , Scheuch , G. , Sommerer , K. , DeLong , M. , Verma , A. , and Batycky , R. ( 2002 ),
In vitro and in vivo dose delivery characteristics of large porous particles for inhalation ,
Int. J. Pharm. , 245 , 179 – 189 .
178. Bartus , R. T. , Emerich , D. , Snodgrass - Belt , P. , et al. ( 2004 ), A pulmonary formulation of
l - dopa enhances its effectiveness in a rat model of parkinson ’ s disease , J. Pharmacol.
Exp. Ther. , 310 , 828 – 835 .
179. Dellamary , L. A. , Tarara , T. E. , Smith , D. J. , et al. ( 2000 ), Hollow porous particles in
metered dose inhalers , Pharm. Res. , 17 , 168 – 174 .
180. Duddu , S. P. , Sisk , S. A. , Walter , Y. H. , et al. ( 2002 ), Improved lung delivery from a passive
dry powder inhaler using an engineered PulmoSphere powder , Pharm. Res. , 19 ,
689 – 695 .
181. Pfutzner , A. , Mann , A. E. , and Steiner , S. S. ( 2002 ), Technosphere/Insulin — A new
approach for effective delivery of human insulin via the pulmonary route , Diabetes
Technol. Ther. , 4 , 589 – 594 .
182. Pfutzner , A. , Flacke , F. , Pohl , R. , et al. ( 2003 ), Pilot study with technosphere/PTH
(1 - 34) — A new approach for effective pulmonary delivery of parathyroid hormone (1 -
34) , Horm. Metab. Res. , 35 , 319 – 323 .
183. Young , P. M. , and Price , R. ( 2004 ), The infl uence of humidity on the aerosolisation of
micronised and SEDS produced salbutamol sulphate , Eur. J. Pharm. Sci. , 22 , 235 – 240 .
184. Rehman , M. , Shekunov , B. Y. , York , P. , et al. Optimisation of powders for pulmonary
delivery using supercritical fl uid technology , Eur. J. Pharm. Sci. , 22 , 1 – 17 .
185. Lobo , J. M. , Schiavone , H. , Palakodaty , S. , York , P. , Clark , A. , and Tzannis , S. T. ( 2005 ),
SCF - engineered powders for delivery of budesonide from passive DPI devices , J. Pharm.
Sci. , 94 , 2276 – 2288 .
186. Schiavone , H. , Palakodaty , S. , Clark , A. , York , P. , and Tzannis , S. T. ( 2004 ), Evaluation of
SCF - engineered particle - based lactose blends in passive dry powder inhalers , Int. J.
Pharm. , 281 , 55 – 66 .
187. Pandey , R. , Sharma , A. , Zahoor , A. , Sharma , S. , Khuller , G. K. , and Prasad , B. ( 2003 ),
Poly ( dl - lactide - co - glycolide) nanoparticle - based inhalable sustained drug delivery
system for experimental tuberculosis , J. Antimicrob. Chemother. , 52 , 981 – 986 .
188. Dickinson , P. A. , Howells , S. W. , and Kellaway , I. W. ( 2001 ), Novel nanoparticles for pulmonary
drug administration , J. Drug Target. , 9 , 295 – 302 .